 | • レポートコード：GIR-2104Z02479 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、画期的治療薬（BT）指定のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。画期的治療薬（BT）指定の種類別市場規模（腫瘍、感染症、希少疾患、自己免疫疾患、肺疾患、神経障害、その他）、用途別市場規模（病院、診療所、研究所、実験室、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・画期的治療薬（BT）指定の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Roche、Abbvie、Novartis International AG、Janssen、BMS、Eli Lilly、Gilead、Sanofi、Regeneron、Acadia、Boehringer Ingelheim、Amgen、AstraZeneca、GlaxoSmithKline、Vertex、Alexion、Merck、Jazz Pharmaceuticals、Exelixis、Eisai、Takeda、Pfizer ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：腫瘍、感染症、希少疾患、自己免疫疾患、肺疾患、神経障害、その他 ・用途別分析2016年-2026年：病院、診療所、研究所、実験室、その他 ・画期的治療薬（BT）指定の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・画期的治療薬（BT）指定のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・画期的治療薬（BT）指定のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・画期的治療薬（BT）指定の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・画期的治療薬（BT）指定の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Breakthrough Therapy (BT) Designation market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Breakthrough Therapy (BT) Designation size is estimated to be USD 69830 million in 2025 from USD 51990 million in 2019, with a change XX% between 2019 and 2020. The global Breakthrough Therapy (BT) Designation market size is expected to grow at a CAGR of 7.7% for the next five years.
Market segmentation
Breakthrough Therapy (BT) Designation market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Oncology
Infectious Diseases
Rare Diseases
Autoimmune Diseases
Pulmonary Diseases
Neurological Disorders
Others
Market segment by Application, can be divided into
Hospital
Clinic
Research Institute
Laboratories
Others
Market segment by players, this report covers
Roche
Abbvie
Novartis International AG
Janssen
BMS
Eli Lilly
Gilead
Sanofi
Regeneron
Acadia
Boehringer Ingelheim
Amgen
AstraZeneca
GlaxoSmithKline
Vertex
Alexion
Merck
Jazz Pharmaceuticals
Exelixis
Eisai
Takeda
Pfizer
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Breakthrough Therapy (BT) Designation
1.2 Classification of Breakthrough Therapy (BT) Designation by Type
1.2.1 Overview: Global Breakthrough Therapy (BT) Designation Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type in 2020
1.2.3 Oncology
1.2.4 Infectious Diseases
1.2.5 Rare Diseases
1.2.6 Autoimmune Diseases
1.2.7 Pulmonary Diseases
1.2.8 Neurological Disorders
1.2.9 Others
1.3 Global Breakthrough Therapy (BT) Designation Market by Application
1.3.1 Overview: Global Breakthrough Therapy (BT) Designation Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Laboratories
1.3.6 Others
1.4 Global Breakthrough Therapy (BT) Designation Market Size & Forecast
1.5 Global Breakthrough Therapy (BT) Designation Market Size and Forecast by Region
1.5.1 Global Breakthrough Therapy (BT) Designation Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Breakthrough Therapy (BT) Designation Market Size by Region, (2016-2021)
1.5.3 North America Breakthrough Therapy (BT) Designation Market Size and Prospect (2016-2026)
1.5.4 Europe Breakthrough Therapy (BT) Designation Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size and Prospect (2016-2026)
1.5.6 South America Breakthrough Therapy (BT) Designation Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Breakthrough Therapy (BT) Designation Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Breakthrough Therapy (BT) Designation Market Drivers
1.6.2 Breakthrough Therapy (BT) Designation Market Restraints
1.6.3 Breakthrough Therapy (BT) Designation Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Breakthrough Therapy (BT) Designation Product and Solutions
2.1.4 Roche Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Abbvie
2.2.1 Abbvie Details
2.2.2 Abbvie Major Business
2.2.3 Abbvie Breakthrough Therapy (BT) Designation Product and Solutions
2.2.4 Abbvie Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Abbvie Recent Developments and Future Plans
2.3 Novartis International AG
2.3.1 Novartis International AG Details
2.3.2 Novartis International AG Major Business
2.3.3 Novartis International AG Breakthrough Therapy (BT) Designation Product and Solutions
2.3.4 Novartis International AG Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Novartis International AG Recent Developments and Future Plans
2.4 Janssen
2.4.1 Janssen Details
2.4.2 Janssen Major Business
2.4.3 Janssen Breakthrough Therapy (BT) Designation Product and Solutions
2.4.4 Janssen Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Janssen Recent Developments and Future Plans
2.5 BMS
2.5.1 BMS Details
2.5.2 BMS Major Business
2.5.3 BMS Breakthrough Therapy (BT) Designation Product and Solutions
2.5.4 BMS Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 BMS Recent Developments and Future Plans
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Breakthrough Therapy (BT) Designation Product and Solutions
2.6.4 Eli Lilly Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Eli Lilly Recent Developments and Future Plans
2.7 Gilead
2.7.1 Gilead Details
2.7.2 Gilead Major Business
2.7.3 Gilead Breakthrough Therapy (BT) Designation Product and Solutions
2.7.4 Gilead Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Gilead Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Breakthrough Therapy (BT) Designation Product and Solutions
2.8.4 Sanofi Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Regeneron
2.9.1 Regeneron Details
2.9.2 Regeneron Major Business
2.9.3 Regeneron Breakthrough Therapy (BT) Designation Product and Solutions
2.9.4 Regeneron Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Regeneron Recent Developments and Future Plans
2.10 Acadia
2.10.1 Acadia Details
2.10.2 Acadia Major Business
2.10.3 Acadia Breakthrough Therapy (BT) Designation Product and Solutions
2.10.4 Acadia Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Acadia Recent Developments and Future Plans
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business
2.11.3 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Product and Solutions
2.11.4 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Boehringer Ingelheim Recent Developments and Future Plans
2.12 Amgen
2.12.1 Amgen Details
2.12.2 Amgen Major Business
2.12.3 Amgen Breakthrough Therapy (BT) Designation Product and Solutions
2.12.4 Amgen Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Amgen Recent Developments and Future Plans
2.13 AstraZeneca
2.13.1 AstraZeneca Details
2.13.2 AstraZeneca Major Business
2.13.3 AstraZeneca Breakthrough Therapy (BT) Designation Product and Solutions
2.13.4 AstraZeneca Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 AstraZeneca Recent Developments and Future Plans
2.14 GlaxoSmithKline
2.14.1 GlaxoSmithKline Details
2.14.2 GlaxoSmithKline Major Business
2.14.3 GlaxoSmithKline Breakthrough Therapy (BT) Designation Product and Solutions
2.14.4 GlaxoSmithKline Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 GlaxoSmithKline Recent Developments and Future Plans
2.15 Vertex
2.15.1 Vertex Details
2.15.2 Vertex Major Business
2.15.3 Vertex Breakthrough Therapy (BT) Designation Product and Solutions
2.15.4 Vertex Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Vertex Recent Developments and Future Plans
2.16 Alexion
2.16.1 Alexion Details
2.16.2 Alexion Major Business
2.16.3 Alexion Breakthrough Therapy (BT) Designation Product and Solutions
2.16.4 Alexion Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Alexion Recent Developments and Future Plans
2.17 Merck
2.17.1 Merck Details
2.17.2 Merck Major Business
2.17.3 Merck Breakthrough Therapy (BT) Designation Product and Solutions
2.17.4 Merck Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Merck Recent Developments and Future Plans
2.18 Jazz Pharmaceuticals
2.18.1 Jazz Pharmaceuticals Details
2.18.2 Jazz Pharmaceuticals Major Business
2.18.3 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Product and Solutions
2.18.4 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Jazz Pharmaceuticals Recent Developments and Future Plans
2.19 Exelixis
2.19.1 Exelixis Details
2.19.2 Exelixis Major Business
2.19.3 Exelixis Breakthrough Therapy (BT) Designation Product and Solutions
2.19.4 Exelixis Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Exelixis Recent Developments and Future Plans
2.20 Eisai
2.20.1 Eisai Details
2.20.2 Eisai Major Business
2.20.3 Eisai Breakthrough Therapy (BT) Designation Product and Solutions
2.20.4 Eisai Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Eisai Recent Developments and Future Plans
2.21 Takeda
2.21.1 Takeda Details
2.21.2 Takeda Major Business
2.21.3 Takeda Breakthrough Therapy (BT) Designation Product and Solutions
2.21.4 Takeda Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Takeda Recent Developments and Future Plans
2.22 Pfizer
2.22.1 Pfizer Details
2.22.2 Pfizer Major Business
2.22.3 Pfizer Breakthrough Therapy (BT) Designation Product and Solutions
2.22.4 Pfizer Breakthrough Therapy (BT) Designation Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Breakthrough Therapy (BT) Designation Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Breakthrough Therapy (BT) Designation Players Market Share
3.2.2 Top 10 Breakthrough Therapy (BT) Designation Players Market Share
3.2.3 Market Competition Trend
3.3 Breakthrough Therapy (BT) Designation Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Breakthrough Therapy (BT) Designation Revenue and Market Share by Type (2016-2021)
4.2 Global Breakthrough Therapy (BT) Designation Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Application (2016-2021)
5.2 Breakthrough Therapy (BT) Designation Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Breakthrough Therapy (BT) Designation Revenue by Type (2016-2026)
6.2 North America Breakthrough Therapy (BT) Designation Revenue by Application (2016-2026)
6.3 North America Breakthrough Therapy (BT) Designation Market Size by Country
6.3.1 North America Breakthrough Therapy (BT) Designation Revenue by Country (2016-2026)
6.3.2 United States Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
6.3.3 Canada Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
6.3.4 Mexico Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Breakthrough Therapy (BT) Designation Revenue by Type (2016-2026)
7.2 Europe Breakthrough Therapy (BT) Designation Revenue by Application (2016-2026)
7.3 Europe Breakthrough Therapy (BT) Designation Market Size by Country
7.3.1 Europe Breakthrough Therapy (BT) Designation Revenue by Country (2016-2026)
7.3.2 Germany Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
7.3.3 France Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
7.3.5 Russia Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
7.3.6 Italy Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Type (2016-2026)
8.2 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Application (2016-2026)
8.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region
8.3.1 Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Region (2016-2026)
8.3.2 China Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
8.3.3 Japan Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
8.3.4 South Korea Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
8.3.5 India Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
8.3.7 Australia Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Breakthrough Therapy (BT) Designation Revenue by Type (2016-2026)
9.2 South America Breakthrough Therapy (BT) Designation Revenue by Application (2016-2026)
9.3 South America Breakthrough Therapy (BT) Designation Market Size by Country
9.3.1 South America Breakthrough Therapy (BT) Designation Revenue by Country (2016-2026)
9.3.2 Brazil Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
9.3.3 Argentina Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Type (2016-2026)
10.2 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Application (2016-2026)
10.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country
10.3.1 Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Country (2016-2026)
10.3.2 Turkey Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
10.3.4 UAE Breakthrough Therapy (BT) Designation Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Breakthrough Therapy (BT) Designation Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Breakthrough Therapy (BT) Designation Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Breakthrough Therapy (BT) Designation Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Breakthrough Therapy (BT) Designation Revenue (USD Million) by Region (2016-2021)
Table 5. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Region (2021-2026)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Breakthrough Therapy (BT) Designation Product and Solutions
Table 9. Roche Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Abbvie Corporate Information, Head Office, and Major Competitors
Table 11. Abbvie Major Business
Table 12. Abbvie Breakthrough Therapy (BT) Designation Product and Solutions
Table 13. Abbvie Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Novartis International AG Corporate Information, Head Office, and Major Competitors
Table 15. Novartis International AG Major Business
Table 16. Novartis International AG Breakthrough Therapy (BT) Designation Product and Solutions
Table 17. Novartis International AG Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Janssen Corporate Information, Head Office, and Major Competitors
Table 19. Janssen Major Business
Table 20. Janssen Breakthrough Therapy (BT) Designation Product and Solutions
Table 21. Janssen Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. BMS Corporate Information, Head Office, and Major Competitors
Table 23. BMS Major Business
Table 24. BMS Breakthrough Therapy (BT) Designation Product and Solutions
Table 25. BMS Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly Major Business
Table 28. Eli Lilly Breakthrough Therapy (BT) Designation Product and Solutions
Table 29. Eli Lilly Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Gilead Corporate Information, Head Office, and Major Competitors
Table 31. Gilead Major Business
Table 32. Gilead Breakthrough Therapy (BT) Designation Product and Solutions
Table 33. Gilead Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Breakthrough Therapy (BT) Designation Product and Solutions
Table 37. Sanofi Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Regeneron Corporate Information, Head Office, and Major Competitors
Table 39. Regeneron Major Business
Table 40. Regeneron Breakthrough Therapy (BT) Designation Product and Solutions
Table 41. Regeneron Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Acadia Corporate Information, Head Office, and Major Competitors
Table 43. Acadia Major Business
Table 44. Acadia Breakthrough Therapy (BT) Designation Product and Solutions
Table 45. Acadia Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 47. Boehringer Ingelheim Major Business
Table 48. Boehringer Ingelheim Breakthrough Therapy (BT) Designation Product and Solutions
Table 49. Boehringer Ingelheim Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Amgen Corporate Information, Head Office, and Major Competitors
Table 51. Amgen Major Business
Table 52. Amgen Breakthrough Therapy (BT) Designation Product and Solutions
Table 53. Amgen Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 55. AstraZeneca Major Business
Table 56. AstraZeneca Breakthrough Therapy (BT) Designation Product and Solutions
Table 57. AstraZeneca Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 59. GlaxoSmithKline Major Business
Table 60. GlaxoSmithKline Breakthrough Therapy (BT) Designation Product and Solutions
Table 61. GlaxoSmithKline Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Vertex Corporate Information, Head Office, and Major Competitors
Table 63. Vertex Major Business
Table 64. Vertex Breakthrough Therapy (BT) Designation Product and Solutions
Table 65. Vertex Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Alexion Corporate Information, Head Office, and Major Competitors
Table 67. Alexion Major Business
Table 68. Alexion Breakthrough Therapy (BT) Designation Product and Solutions
Table 69. Alexion Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Merck Corporate Information, Head Office, and Major Competitors
Table 71. Merck Major Business
Table 72. Merck Breakthrough Therapy (BT) Designation Product and Solutions
Table 73. Merck Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Jazz Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 75. Jazz Pharmaceuticals Major Business
Table 76. Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Product and Solutions
Table 77. Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Exelixis Corporate Information, Head Office, and Major Competitors
Table 79. Exelixis Major Business
Table 80. Exelixis Breakthrough Therapy (BT) Designation Product and Solutions
Table 81. Exelixis Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Eisai Corporate Information, Head Office, and Major Competitors
Table 83. Eisai Major Business
Table 84. Eisai Breakthrough Therapy (BT) Designation Product and Solutions
Table 85. Eisai Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Takeda Corporate Information, Head Office, and Major Competitors
Table 87. Takeda Major Business
Table 88. Takeda Breakthrough Therapy (BT) Designation Product and Solutions
Table 89. Takeda Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Pfizer Corporate Information, Head Office, and Major Competitors
Table 91. Pfizer Major Business
Table 92. Pfizer Breakthrough Therapy (BT) Designation Product and Solutions
Table 93. Pfizer Breakthrough Therapy (BT) Designation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Global Breakthrough Therapy (BT) Designation Revenue (USD Million) by Players (2019-2021)
Table 95. Global Breakthrough Therapy (BT) Designation Revenue Share by Players (2019-2021)
Table 96. Breakdown of Breakthrough Therapy (BT) Designation by Company Type (Tier 1, Tier 2 and Tier 3)
Table 97. Breakthrough Therapy (BT) Designation Players Head Office, Products and Services Provided
Table 98. Breakthrough Therapy (BT) Designation Mergers & Acquisitions in the Past Five Years
Table 99. Breakthrough Therapy (BT) Designation New Entrants and Expansion Plans
Table 100. Global Breakthrough Therapy (BT) Designation Revenue (USD Million) by Type (2016-2021)
Table 101. Global Breakthrough Therapy (BT) Designation Revenue Share by Type (2016-2021)
Table 102. Global Breakthrough Therapy (BT) Designation Revenue Forecast by Type (2021-2026)
Table 103. Global Breakthrough Therapy (BT) Designation Revenue by Application (2016-2021)
Table 104. Global Breakthrough Therapy (BT) Designation Revenue Forecast by Application (2021-2026)
Table 105. North America Breakthrough Therapy (BT) Designation Revenue by Type (2016-2021) & (USD Million)
Table 106. North America Breakthrough Therapy (BT) Designation Revenue by Type (2021-2026) & (USD Million)
Table 107. North America Breakthrough Therapy (BT) Designation Revenue by Application (2016-2021) & (USD Million)
Table 108. North America Breakthrough Therapy (BT) Designation Revenue by Application (2021-2026) & (USD Million)
Table 109. North America Breakthrough Therapy (BT) Designation Revenue by Country (2016-2021) & (USD Million)
Table 110. North America Breakthrough Therapy (BT) Designation Revenue by Country (2021-2026) & (USD Million)
Table 111. Europe Breakthrough Therapy (BT) Designation Revenue by Type (2016-2021) & (USD Million)
Table 112. Europe Breakthrough Therapy (BT) Designation Revenue by Type (2021-2026) & (USD Million)
Table 113. Europe Breakthrough Therapy (BT) Designation Revenue by Application (2016-2021) & (USD Million)
Table 114. Europe Breakthrough Therapy (BT) Designation Revenue by Application (2021-2026) & (USD Million)
Table 115. Europe Breakthrough Therapy (BT) Designation Revenue by Country (2016-2021) & (USD Million)
Table 116. Europe Breakthrough Therapy (BT) Designation Revenue by Country (2021-2026) & (USD Million)
Table 117. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Type (2016-2021) & (USD Million)
Table 118. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Type (2021-2026) & (USD Million)
Table 119. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Application (2016-2021) & (USD Million)
Table 120. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Application (2021-2026) & (USD Million)
Table 121. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Region (2016-2021) & (USD Million)
Table 122. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue by Region (2021-2026) & (USD Million)
Table 123. South America Breakthrough Therapy (BT) Designation Revenue by Type (2016-2021) & (USD Million)
Table 124. South America Breakthrough Therapy (BT) Designation Revenue by Type (2021-2026) & (USD Million)
Table 125. South America Breakthrough Therapy (BT) Designation Revenue by Application (2016-2021) & (USD Million)
Table 126. South America Breakthrough Therapy (BT) Designation Revenue by Application (2021-2026) & (USD Million)
Table 127. South America Breakthrough Therapy (BT) Designation Revenue by Country (2016-2021) & (USD Million)
Table 128. South America Breakthrough Therapy (BT) Designation Revenue by Country (2021-2026) & (USD Million)
Table 129. Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Type (2016-2021) & (USD Million)
Table 130. Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Type (2021-2026) & (USD Million)
Table 131. Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Application (2016-2021) & (USD Million)
Table 132. Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Application (2021-2026) & (USD Million)
Table 133. Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Country (2016-2021) & (USD Million)
Table 134. Middle East & Africa Breakthrough Therapy (BT) Designation Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Breakthrough Therapy (BT) Designation Picture
Figure 2. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type in 2020
Figure 3. Oncology
Figure 4. Infectious Diseases
Figure 5. Rare Diseases
Figure 6. Autoimmune Diseases
Figure 7. Pulmonary Diseases
Figure 8. Neurological Disorders
Figure 9. Others
Figure 10. Breakthrough Therapy (BT) Designation Revenue Market Share by Application in 2020
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Research Institute Picture
Figure 14. Laboratories Picture
Figure 15. Others Picture
Figure 16. Global Breakthrough Therapy (BT) Designation Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 17. Global Breakthrough Therapy (BT) Designation Revenue and Forecast (2016-2026) & (USD Million)
Figure 18. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Region (2016-2026)
Figure 19. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Region in 2020
Figure 20. North America Breakthrough Therapy (BT) Designation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Europe Breakthrough Therapy (BT) Designation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. South America Breakthrough Therapy (BT) Designation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Breakthrough Therapy (BT) Designation Market Drivers
Figure 25. Breakthrough Therapy (BT) Designation Market Restraints
Figure 26. Breakthrough Therapy (BT) Designation Market Trends
Figure 27. Roche Recent Developments and Future Plans
Figure 28. Abbvie Recent Developments and Future Plans
Figure 29. Novartis International AG Recent Developments and Future Plans
Figure 30. Janssen Recent Developments and Future Plans
Figure 31. BMS Recent Developments and Future Plans
Figure 32. Eli Lilly Recent Developments and Future Plans
Figure 33. Gilead Recent Developments and Future Plans
Figure 34. Sanofi Recent Developments and Future Plans
Figure 35. Regeneron Recent Developments and Future Plans
Figure 36. Acadia Recent Developments and Future Plans
Figure 37. Boehringer Ingelheim Recent Developments and Future Plans
Figure 38. Amgen Recent Developments and Future Plans
Figure 39. AstraZeneca Recent Developments and Future Plans
Figure 40. GlaxoSmithKline Recent Developments and Future Plans
Figure 41. Vertex Recent Developments and Future Plans
Figure 42. Alexion Recent Developments and Future Plans
Figure 43. Merck Recent Developments and Future Plans
Figure 44. Jazz Pharmaceuticals Recent Developments and Future Plans
Figure 45. Exelixis Recent Developments and Future Plans
Figure 46. Eisai Recent Developments and Future Plans
Figure 47. Takeda Recent Developments and Future Plans
Figure 48. Pfizer Recent Developments and Future Plans
Figure 50. Global Breakthrough Therapy (BT) Designation Revenue Share by Players in 2020
Figure 51. Breakthrough Therapy (BT) Designation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 52. Global Top 3 Players Breakthrough Therapy (BT) Designation Revenue Market Share in 2020
Figure 53. Global Top 10 Players Breakthrough Therapy (BT) Designation Revenue Market Share in 2020
Figure 54. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 55. Global Breakthrough Therapy (BT) Designation Revenue Share by Type in 2020
Figure 56. Global Breakthrough Therapy (BT) Designation Market Share Forecast by Type (2021-2026)
Figure 57. Global Breakthrough Therapy (BT) Designation Revenue Share by Application in 2020
Figure 58. Global Breakthrough Therapy (BT) Designation Market Share Forecast by Application (2021-2026)
Figure 59. North America Breakthrough Therapy (BT) Designation Sales Market Share by Type (2016-2026)
Figure 60. North America Breakthrough Therapy (BT) Designation Sales Market Share by Application (2016-2026)
Figure 61. North America Breakthrough Therapy (BT) Designation Revenue Market Share by Country (2016-2026)
Figure 62. United States Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Canada Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Mexico Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Europe Breakthrough Therapy (BT) Designation Sales Market Share by Type (2016-2026)
Figure 66. Europe Breakthrough Therapy (BT) Designation Sales Market Share by Application (2016-2026)
Figure 67. Europe Breakthrough Therapy (BT) Designation Revenue Market Share by Country (2016-2026)
Figure 68. Germany Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. France Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. United Kingdom Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Russia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Italy Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Asia-Pacific Breakthrough Therapy (BT) Designation Sales Market Share by Type (2016-2026)
Figure 74. Asia-Pacific Breakthrough Therapy (BT) Designation Sales Market Share by Application (2016-2026)
Figure 75. Asia-Pacific Breakthrough Therapy (BT) Designation Revenue Market Share by Region (2016-2026)
Figure 76. China Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Japan Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Korea Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. India Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Southeast Asia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Australia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. South America Breakthrough Therapy (BT) Designation Sales Market Share by Type (2016-2026)
Figure 83. South America Breakthrough Therapy (BT) Designation Sales Market Share by Application (2016-2026)
Figure 84. South America Breakthrough Therapy (BT) Designation Revenue Market Share by Country (2016-2026)
Figure 85. Brazil Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Argentina Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Middle East and Africa Breakthrough Therapy (BT) Designation Sales Market Share by Type (2016-2026)
Figure 88. Middle East and Africa Breakthrough Therapy (BT) Designation Sales Market Share by Application (2016-2026)
Figure 89. Middle East and Africa Breakthrough Therapy (BT) Designation Revenue Market Share by Country (2016-2026)
Figure 90. Turkey Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 91. Saudi Arabia Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 92. UAE Breakthrough Therapy (BT) Designation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 93. Methodology
Figure 94. Research Process and Data Source
世界の画期的治療薬市場規模・現状・予測（2021年-2027年） Breakthrough therapy drugs are intended to treat serious and life-threatening conditions. The breakthrough therapy is the designation given by FDA for the drugs when there is a preliminary clinical evidence indicates that the drug proves a substantial improvement over available drug treatment. Two f…- 世界の希少疾患市場規模・現状・予測（2021年-2027年） An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases hav…
- 世界の自己免疫疾患治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Autoimmune Diseases Treatment Market The global Autoimmune Diseases Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integ…
- 世界の動物用自己免疫疾患検査市場規模・現状・予測（2021年-2027年） Animal autoimmune diseases are the result of specific immune responses and directed against self. Animals have the ability to control immune aggression. It acquired the capacity to avoid self-reaction called as tolerance, which allows removal of antigenic pathogens in the absence of self-recognition…
- 世界の動物用自己免疫疾患検査市場規模・現状・予測（2021年-2027年） Animal autoimmune diseases are the result of specific immune responses and directed against self. Animals have the ability to control immune aggression. It acquired the capacity to avoid self-reaction called as tolerance, which allows removal of antigenic pathogens in the absence of self-recognition…